Inverness Medical Innovations & PSAwatch

Inverness Medical Schedules Conference Call for 10:00 a.m. ET April 27, 2009 to Discuss First Quarter 2009 Results


Filed under News on Tuesday, April 21, 2009.
Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 27, 2009 to Discuss First Quarter 2009 Results
WALTHAM, Mass., April 20, 2009 -- Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced that it will release its first quarter 2009 earnings on Monday, April 27, 2009. The Company will also host a conference call beginning at 10:00 a.m. (Eastern Time) on that date to discuss these results and other corporate matters. During the conference call, the Company may discuss and answer questions concerning business and financial developments and trends. The Company's responses to questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been disclosed previously.
The conference call may be accessed by dialing 706-679-1656 (domestic and international), an access code is not required, or via a link on the Inverness website at http://www.invmed.com/. It is also available via link at https://event.meetingstream.com/r.htm?e=143196&s=1&k=B623F2CFEF254698763484BC6914EF4B. An archive of the call will be available from the same link approximately two hours after the live call has concluded and will be accessible for 90 days.
By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life at home. Inverness’ global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women’s health. Inverness is headquartered in Waltham, Massachusetts.
For additional information on Inverness Medical Innovations, please visit http://www.invmed.com/.
Inverness Medical Schedules Conference Call for 10:00 a.m. ET April 27,2009 to Discuss First Quarter 2009 Results 21st April





Five year global distribution agreement secured.

Five year global distribution agreement secured with Inverness Medical InnovationsMediwatch plc (“Mediwatch” or “the Company”, AIM: MDW), the innovative urological diagnostic company, has signed a five-year agreement for the worldwide distribution of PSAwatch, its flagship point-of-care total PSA measuring system for prostate cancer, with Inverness Medical Innovations, Inc. (“Inverness”, NYSE: IMA) a leading provider of near-patient diagnostics, monitoring and health management solutions.

This is a very important and substantial distribution agreement for Mediwatch as Inverness has an extensive global sales-force which will complement Mediwatch’s own worldwide distribution network and provide the Company with considerably more market reach.

Inverness is recognised as a market leader with significant expertise in marketing point-of-care tests, which they already manufacture for other pathological conditions.

Prostate cancer is the second most common cause of cancer deaths with 670,000 men worldwide diagnosed with it annually. Approximately 10,000 men die every year in the UK from prostate cancer with over 34,000 diagnosed with the disease (Source: Cancer Research UK). There are 60 million PSA tests globally with PSAwatch the first quantitative, point-of-care PSA test in this £300 million market. It uses the Mediwatch Bioscan reader and therefore does not require laboratories.

Philip Stimpson, Mediwatch Chief Executive commented’“We are confident that this strategically important distribution agreement will deliver a significant revenue stream.

The market for point of care diagnostics is growing rapidly as a result of a combination of; the population aging, growth of local clinics, home testing and the need for faster, cheaper, more portable and easier to use medical equipment.“This is a significant development for Mediwatch as it means we can both actively promote worldwide the early diagnosis of prostate cancer, with portable rapid-testing equipment.

This is particularly poignant and gratifying for us, being a British company, as this is Prostate Cancer Awareness Month in the UK.”
Five year global distribution agreement secured. 16th March